Millrace Asset Group, Inc. Myriad Genetics Inc Transaction History

Millrace Asset Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$22.08 - $47.08 $645,221 - $1.38 Million	-29,222 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$22.67 - $35.0 $659,243 - $1.02 Million	-29,080 Reduced 49.88%	29,222 $812,000
Q1 2019 May 14, 2019	BUY	$26.93 - $34.7 $148,411 - $191,231	5,511 Added 10.44%	58,302 $1.94 Million
Q4 2018 Feb 13, 2019	BUY	$27.23 - $45.56 $376,291 - $629,593	13,819 Added 35.46%	52,791 $1.53 Million
Q3 2018 Nov 13, 2018	SELL	$37.57 - $50.34 $657,475 - $880,950	-17,500 Reduced 30.99%	38,972 $1.79 Million
Q2 2018 Aug 14, 2018	BUY	$27.75 - $40.17 $935,175 - $1.35 Million	33,700 Added 147.99%	56,472 $2.11 Million
Q1 2018 May 15, 2018	SELL	$28.83 - $41.01 $261,372 - $371,796	-9,066 Reduced 28.48%	22,772 $673,000
Q4 2017 Feb 13, 2018	SELL	$28.45 - $37.14 $25,605 - $33,426	-900 Reduced 2.75%	31,838 $1.09 Million
Q3 2017 Nov 13, 2017	SELL	$24.01 - $36.2 $1.08 Million - $1.63 Million	-45,103 Reduced 57.94%	32,738 $1.18 Million
Q2 2017 Aug 11, 2017	BUY	N/A	77,841	77,841 $2.01 Million

253

90.9M

100K

34K

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.25B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

Get notified when there are updates to the investment portfolio of Millrace Asset Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Millrace Asset Group, Inc. with notifications on news.